Travoprost With Timolol Maleate, Eye Drops
Recommended OphthalmologyRestrictedLater-line line
Reduction of elevated intra-ocular pressure in patients with open angle glaucoma or ocular hypertension, who are not adequately controlled with beta-blockers or prostaglandin analogues.
2
Submissions
1 resub
2006–07
On the record
—
ICER range
Cost-min
Cost basis
Decisions on record
- Meeting Mar 2009 Recommended Anti-glaucoma
- Meeting Mar 2007 Recommended Glaucoma
Access path
- Jul 2006Recommended · restricted
vs fixed dose combination of latanoprost with timolol maleate…
- Mar 2007Recommended · restricted
Comparator changed: fixed dose combination of latanoprost with timolol maleate (Xalacom®)…
- PBS listing · Restricted
RecommendedDeferredNot recommended
Cost-effectiveness
Cost minimisation basis; no economic evaluation presented
Decision context
Populationpatients with open angle glaucoma or ocular hypertension, who are not adequately controlled with beta-blockers or prostaglandin analogues
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Mar 2007 | Recommended · restricted | concomitant administration of latanoprost and timolol | — | RCT |
| Jul 2006 | Recommended · restricted | fixed dose combination of latanoprost with timolol maleate (Xalacom®) | — | RCT · OS | PFS | DFS | ORR | QoL | Surrogate | Cost-minimisation | Other | null |
Similar precedents
Travoprost With Timolol Maleate87%Latanoprost With Timolol Maleate84%Bimatoprost With Timolol Maleate83%Betaxolol, Bimatoprost, Bimatoprost + Timolol, Brimonidine, Brimonidine + Timolol, Brinzolamide, Brinzolamide + Timolol, Dorzolamide, Dorzolamide + Timolol, Latanoprost, Latanoprost + Timolol, Pilocarpine, Timolol, Travoprost, Timolol + Travoprost83%Dorzolamide Hydrochloride With Timolol Maleate, Eye Drops82%Brinzolamide/Brimonidine Tartrate79%Dorzolamide With Timolol78%Tafluprost77%
Regulatory · TGA
Label narrower than PBS population — PBAC restricts to patients inadequately controlled with beta-blockers or prostaglandin analogues; TGA label requires only insufficient single-agent control.